THE PROGNOSTIC-SIGNIFICANCE OF RESIDUAL DISEASE, FIGO SUBSTAGE, TUMOR HISTOLOGY, AND GRADE IN PATIENTS WITH FIGO STAGE-III OVARIAN-CANCER

被引:206
作者
MAKAR, AP [1 ]
BAEKELANDT, M [1 ]
TROPE, CG [1 ]
KRISTENSEN, GB [1 ]
机构
[1] NORWEGIAN RADIUM HOSP,DEPT GYNECOL ONCOL,N-0310 OSLO,NORWAY
关键词
D O I
10.1006/gyno.1995.1027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Survival was evaluated in 455 patients with FIGO stage III invasive ovarian cancer managed between 1983 and 1991. Median follow-up was 73 months. The prognostic significance of clinical and histopathological variables was evaluated. In Cox multivariate analysis, FIGO substage was an independent prognostic factor with a relative hazard (RH) of 1.2 and 1.7 for substage IIIB and IIIC, respectively (P = 0.013). Size of residual disease after surgery was a stronger factor with an RH of 1.2 and 2.4 for residual disease of 0 to 2 cm and more than 2 cm, respectively (P < 0.001). Histologic type had prognostic significance because patients with endometrioid tumors did best, those with mixed, serous, and unclassified tumors had an RH of 1.5 to 1.9, and those with mucinous and clear cell tumors had an RH of 5.4 to 7 (P < 0.001). Grade, ascites, and age had also independent significance. Grade had an RH of 2.5 for grade 2 plus 3 (P < 0.001), ascites had an RH of 1.4 (P 0.018), and age had an RH of 1.7 and 2.4 for age 40 to 70 years and above 70 years, respectively (P < 0.001). (C) 1995 Academic Press, Inc.
引用
收藏
页码:175 / 180
页数:6
相关论文
共 30 条
[1]  
AURE JC, 1971, OBSTET GYNECOL, V37, P1
[2]   IMPROVED PROGNOSIS OF OVARIAN-CANCER IN THE NETHERLANDS DURING THE PERIOD 1975-1985 - A REGISTRY-BASED STUDY [J].
BALVERTLOCHT, HR ;
COEBERGH, JWW ;
HOP, WCJ ;
BROLMANN, HAM ;
CROMMELIN, M ;
VANWIJCK, DJAM ;
VERHAGENTEULINGS, MTCIJ .
GYNECOLOGIC ONCOLOGY, 1991, 42 (01) :3-8
[3]  
BERTELSEN K, 1990, GYNECOL ONCOL, V38, P230
[4]  
BJORKHOLM E, 1982, ACTA RADIOL ONCOL, V21, P413
[5]  
COLDMAN AJ, 1979, CAN MED ASSOC J, V121, P1065
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   A RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN WITH OR WITHOUT BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUBOPTIMAL STAGE-III AND STAGE-IV OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
CREASMAN, WT ;
OMURA, GA ;
BRADY, MF ;
YORDAN, E ;
DISAIA, PJ ;
BEECHAM, J .
GYNECOLOGIC ONCOLOGY, 1990, 39 (03) :239-243
[8]  
DEMBO AJ, 1990, OBSTET GYNECOL, V75, P263
[9]  
DROZ JP, 1988, HDB CHEMOTHERAPY CLI, P408
[10]  
EINHORN N, 1985, CANCER, V55, P2019, DOI 10.1002/1097-0142(19850501)55:9<2019::AID-CNCR2820550932>3.0.CO